Therapeutics
Immunotherapy (passive)
- Study completed / Planned end date
- Planned end date unavailable
- Study aborted
| Immunotherapy (passive) | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aducanumab |
Phase 3
|
||||||||||||||||||
| BAN2401 |
Phase 1, Phase 2
|
||||||||||||||||||
| Bapineuzumab |
Phase 2, Phase 3
|
||||||||||||||||||
| C2N 8E12 |
Phase 2
|
||||||||||||||||||
| Crenezumab |
Phase 2, Phase 3
|
||||||||||||||||||
| Gamunex |
Phase 2/3
|
||||||||||||||||||
| Gantenerumab |
Phase 2/3, Phase 3
|
||||||||||||||||||
| Octagam®10% |
Phase 2
|
||||||||||||||||||
| Ponezumab |
Phase 2
|
||||||||||||||||||
| Solanezumab |
Phase 2, Phase 2/3, Phase 3
|